- Lower LDL-C and raise HDL-C with a low 10-mg dose of CRESTOR1
- In patients with type 2 diabetes, up to 94%‡ achieved LDL-C goal of <100 mg/dL§ with a starting dose of CRESTOR 10 mg4,14,32
- Safety profile in line with other leading statins1,5,6
‡
3 titration trials of patients with type 2 diabetes treated with a starting dose of CRESTOR 10 mg:
In the ANDROMEDA trial (n=240), 94% reached LDL-C goal of <96.5 mg/dL at 8 weeks. There was a
mean LDL-C reduction of 51% from baseline of 131 mg/dL. The primary end point was the percentage
change from baseline in LDL-C after 16 weeks.
In the CORALL trial (n=130), 82% reached LDL-C goal of <100 mg/dL at 6 weeks. There was a mean
LDL-C reduction of 46% from baseline of 163 mg/dL. The primary end point, the percentage change
from baseline in ApoB/ApoA-1 ratio after 6 weeks, was not significantly different between
CRESTOR and atorvastatin. LDL-C goal achievement was another end point.
In the URANUS trial (n=232), 65% reached LDL-C goal of <100 mg/dL at 4 weeks. There was a
mean LDL-C reduction of 48% from baseline of 178 mg/dL. The primary end point was the percentage
change from baseline in LDL-C after 16 weeks.
§
According to the third report of the National Cholesterol Education Program Adult Treatment
Panel (NCEP ATP III) update, the LDL-C goal is <160 mg/dL for Lower-Risk patients,
<130 mg/dL for Moderate-Risk patients, <130 mg/dL (optional goal of <100 mg/dL) for
Moderately High-Risk patients, <100 mg/dL for High-Risk patients, and an optional goal of
<70 mg/dL for Very High-Risk
patients
2,3.